ReviewMolecular biology reports2026
Crosstalk between neurotransmitters and NLRP3 inflammasome pathway: A narrative review.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neurotransmitters (NTs) are endogenous chemical messengers that critically shape daily functions, influencing emotion, cognition, behavior, and motor activity. The NLRP3 inflammasome bridges innate immunity and neural function. Accumulating evidence indicates that its crosstalk with NT signaling affects both neuroinflammatory processes and the activity of neuronal and glial cells. In this review, we summarize the current evidence on the crosstalk between neurotransmitters (NTs) and the NLRP3 inflammasome under pathological conditions affecting the central nervous system (CNS), where neurotransmitter dysregulation and chronic NLRP3 inflammasome activation coexist. Our review does not support a single, uniform pattern for this interaction; instead, outcomes vary according to the neurotransmitter involved, receptor subtype, cell type, and underlying pathology. Most available studies assess how NTs regulate NLRP3 priming or activation, whereas the reverse influence of NLRP3 signaling on NT release, receptor function, and synaptic plasticity remains less studied. Further investigation of this bidirectional relationship may help inform the development of therapeutic strategies that target NLRP3-NT crosstalk. Given the complex interconnectivity among neurotransmitter systems, integrating their mutual interactions with NLRP3 activity is likely to yield a more comprehensive view of neuroimmune regulation in health and disease. The emerging evidence of dual and context-specific actions for example, biphasic effects of dopamine on neuroinflammation under different experimental conditions underscores the need for mechanistically oriented, disease-specific, and cautiously interpreted studies. Finally, systematic investigation of less-studied neurotransmitters and receptor subtypes may uncover additional regulatory mechanisms within the NLRP3 network and identify potential targets for future therapeutic investigation in neuroinflammatory and neurological disorders.
Indexed as
Identifiers
42776397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.